Astrazheneka India Pharma has received approval from the Government Authority for import, sales and distribution of drugs used in the treatment of non-maximum cell lung cancer. The company gave this information on Thursday. According to PTI news, Astrajneka India said in a statement that the company has received approval from the Central Drug Control Organization (CDSCO) for the 40 mg and 80 mg of Osimrtinib Tablet.
An important step forward
According to the news, this approval has taken a significant step ahead with Osimrtinib as a local advanced, Asfection (Stage III) in the treatment of non-mall cell lung cancer patients as monotherapy. The drug firm stated that this new signal represents the treatment option of a first class for EGFR-upper-converted NSCLC post-keydrop. Sanjeev Panchal, Country President and MD of Astrajeneka Pharma India, said that with the approval of Osimrtinib for this additional indication, we are achieving an important milestone in re -defying the treatment of lung cancer in India.
This medicine was done back
Astrazheneka Pharma India Limited had informed about a month ago that it has returned the treatment of prostate cancer in India, Olaparib (Linparaja) 100MG and 150MG to the Marketing Authority. Astrazheneka Pharma India said in a regulatory filing that the company received the marketing authority for Olaparib Film-Koted Tablet 100mg and 150MG (Linpara) on November 17, 2023.
Earlier, Astrazheneka Pharma India was allowed to import and sell sodium zirconium cyclosilicate powder for oral suspension used in the treatment of hyperkelemia (higher potassium level than normal in blood) from India’s drug regulator two months ago.
Latest business news
